DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Bioactive Compound Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) contains 2,320 clinically approved compounds, each supplied as a 10 mM DMSO solution stable for up to 24 months at -80°C (vendor link). The library encompasses diverse mechanisms of action, including receptor agonists/antagonists and enzyme inhibitors, verified by regulatory agency approvals (FDA, EMA, HMA, CFDA, PMDA) (source). It is optimized for high-throughput and high-content screening (HTS/HCS), supporting drug repositioning and pharmacological pathway exploration. Representative drugs such as doxorubicin and metformin are included. The collection is available in multiple user-friendly formats, supporting rapid integration into diverse research pipelines (related review).

Biological Rationale

Drug discovery and repositioning require validated compound libraries with known safety and pharmacokinetic profiles. Regulatory-approved compound collections offer unique translational value by ensuring all compounds have undergone extensive clinical evaluation for efficacy and toxicity (ApexBio). High-throughput screening (HTS) and high-content screening (HCS) rely on such libraries to efficiently interrogate biological pathways and disease models (see also: pipeline integration). This enables the identification of new indications for existing drugs (drug repositioning), which can accelerate clinical translation and reduce development costs.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ library includes compounds targeting a spectrum of biological mechanisms:

• Receptor Agonists and Antagonists: Modulate cell signaling by activating or blocking receptors (e.g., β-adrenergic antagonists).
• Enzyme Inhibitors: Block enzymatic activity, affecting metabolic or signaling pathways (e.g., kinase inhibitors).
• Ion Channel Modulators: Alter ion conductance, impacting neuronal and cardiac function.
• Signal Pathway Regulators: Influence key disease-relevant cascades (e.g., mTOR, MAPK pathways).

All compounds are pre-dissolved at 10 mM in DMSO, facilitating direct use in screening without additional solubilization. The library is designed for compatibility with both 96-well and deep-well plate formats, supporting automation and scalability in screening workflows (see single-cell applications).

Evidence & Benchmarks

• The DiscoveryProbe™ library contains 2,320 compounds, each with regulatory approval or pharmacopeia listing (ApexBio, product page).
• Solutions are provided at 10 mM concentration in DMSO, stable for 12 months at -20°C and 24 months at -80°C (ApexBio, product specifications).
• Facilitates high-throughput screening of cancer, neurodegenerative, and infectious disease models, as demonstrated in benchmark studies (internal review).
• Enables drug repositioning by leveraging clinical safety data, reducing translational risk (mechanistic guidance).
• In peer-reviewed virology research, similar compound libraries have been used to identify pharmacological inhibitors of host factors such as caspase-3, impacting viral infection outcomes (Song et al., 2025, https://doi.org/10.1126/sciadv.adu7985).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports a range of research applications:

• High-throughput and high-content screening for target identification in oncology, neurodegenerative, and infectious disease research (read more).
• Drug repositioning studies leveraging known safety and pharmacokinetics.
• Mechanistic studies of signaling pathways and enzymatic regulation.

Common Pitfalls or Misconceptions

• The library does not cover investigational or preclinical compounds without regulatory approval; it is limited to clinically approved or pharmacopeia-listed drugs.
• Compounds are supplied in DMSO; water-soluble requirements must be validated by users.
• Therapeutic effects in screening models may not translate directly to all in vivo disease settings without further validation.
• Drug-drug interaction effects are not pre-characterized within the library and require separate investigation.
• The resource is optimized for HTS/HCS workflows and may be less suitable for low-throughput manual assays.

This article extends prior reviews by providing structured evidence and updated stability parameters, as compared to previous summaries and mechanism-focused articles.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is available in 96-well and deep-well microplates, as well as 2D barcoded screw-top tubes. Each well contains a 10 mM DMSO solution, aliquoted for direct pipetting. For HTS/HCS, plates are compatible with most liquid handlers and imaging platforms. Compounds remain stable for 12 months at -20°C and 24 months at -80°C. Shipping is performed on blue ice for evaluation samples or at room temperature/blue ice for other sizes. Users should minimize freeze-thaw cycles to preserve compound integrity (ApexBio).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library delivers a regulatory-anchored, ready-to-use compound resource, accelerating high-throughput screening, drug repositioning, and mechanistic pharmacological studies. Its stability, format flexibility, and comprehensive clinical annotation position it as a gold-standard tool for translational research. Future integration with single-cell analytics and AI-driven screening platforms will further enhance its impact (see next-gen workflows).